Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-01-10
2006-01-10
Raymond, Richard L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S314000, C514S318000, C514S323000, C514S324000, C514S326000, C514S331000, C514S422000, C540S597000, C546S169000, C546S194000, C546S201000, C546S202000, C546S213000, C546S233000, C548S568000
Reexamination Certificate
active
06984637
ABSTRACT:
This invention relates to certain cyclic amine derivatives of Formula (I)that are CCR-3 receptor antagonists, pharmaceutical compositions containing them, methods for their use and methods for preparing these compounds.
REFERENCES:
patent: 3810897 (1974-05-01), Philippe et al.
patent: 4559349 (1985-12-01), Stori
patent: 4579947 (1986-04-01), Devlin et al.
patent: 4778796 (1988-10-01), Uno et al.
patent: 4857330 (1989-08-01), Stephens et al.
patent: 4880808 (1989-11-01), Van Daele et al.
patent: 4882432 (1989-11-01), Abou-Gharbia et al.
patent: 4946843 (1990-08-01), Janssens et al.
patent: 5026858 (1991-06-01), Vega-Noverola et al.
patent: 5081246 (1992-01-01), Hidaka et al.
patent: 5118684 (1992-06-01), Sugimoto et al.
patent: 5143923 (1992-09-01), Hrib et al.
patent: 5364864 (1994-11-01), Bigg et al.
patent: 5434158 (1995-07-01), Shah
patent: 5438064 (1995-08-01), Mobilio et al.
patent: 5622976 (1997-04-01), Takasugi et al.
patent: 5654320 (1997-08-01), Catlow et al.
patent: 5674881 (1997-10-01), Emonds-Alt et al.
patent: 5773620 (1998-06-01), Emonds-Alt et al.
patent: 5837713 (1998-11-01), Gleich
patent: 5849732 (1998-12-01), Suzuki et al.
patent: 5889026 (1999-03-01), Alanine et al.
patent: 6072053 (2000-06-01), Vince et al.
patent: 6090824 (2000-07-01), Bernstein et al.
patent: 6096746 (2000-08-01), Suzuki et al.
patent: 6136827 (2000-10-01), Caldwell et al.
patent: 6166015 (2000-12-01), Rogers et al.
patent: 6235731 (2001-05-01), Shibouta et al.
patent: 00615160 (1980-01-01), None
patent: 02614189 (1977-10-01), None
patent: 0330065 (1989-08-01), None
patent: 0343961 (1989-11-01), None
patent: 0614893 (1994-09-01), None
patent: 0673927 (1995-09-01), None
patent: 0669322 (1996-08-01), None
patent: 0903349 (1999-03-01), None
patent: 62153280 (1987-07-01), None
patent: 02-083375/1990 (1990-03-01), None
patent: 06107546 (1994-04-01), None
patent: 09020759 (1997-01-01), None
patent: 96/28424 (1986-09-01), None
patent: 92/12128 (1992-07-01), None
patent: 95/13069 (1995-05-01), None
patent: 95/19345 (1995-07-01), None
patent: 9710207 (1995-09-01), None
patent: 96/06095 (1996-02-01), None
patent: 97/19060 (1997-05-01), None
patent: 99/37617 (1999-07-01), None
patent: 99/37619 (1999-07-01), None
patent: 0035449 (2000-06-01), None
Archibald, J.L., et al., “136989t Antihypertensive N-4-piperidylbenzamide derivatives”,Chemical Abstracts, 79(23), 1 page, (Dec. 1973).
Boyfield, I., et al., “Design and Synthesis of 2-Naphthoate Esters as Selective Dopamine D4 Antagonist”,American Chemical Society, pp. 1946-1948, (1996).
Harrison, I.T., et al., “Compendium of Organic Synthetic Methods”, xi (index), (1971).
Hase, T.A., et al., “A Compilation of References on R-Functional Acyl Anion Synthons, RCO-”,Aldrichimica Acta, vol. 15, No. 2, 1982, 35-41, (1982).
Heath, H., et al., “Chemokine Receptor Usage by Human Eosinophils, The Importance of CCR3 Demonstrated Using an Antagonistic Monoclonal Antibody”,The American Society for Clinical Investigation, 99(2), pp. 178-184, (Jan. 1997).
Itoh, K., et al., “Synthesis and pharmacological evaluation of carboxamide derivatives as selective serotoninergic 5-HT4 receptor agonists”,Eur. J. Med. Chem., 34, pp. 329-341, (1999).
Ko, S.S., et al., “133:43441b Preparation of N-ureidoalkyl-piperidines as modulators of chemokine receptor activity”,Chemical Abstracts, 133(4), 1 page, (Jul. 2000).
Saxena, M., et al., “Synthesis. Biological Evaluation, and Quantitative Structure-Activity Relationship Analysis of (B-(Aroylamino)ethyl)piperazines and -piperidines and (2-((Arylamino)carbon)ethyl)piperazines,—piperidines, pyrazinpyridoindoles, and -pyrazinoisoquinolines.”,American Chemical Society, pp. 2970-2976, (1990).
Townsend, L.B., “Chemistry of the Heterocyclic Moiety of Purine Nucleosides and Some Closely Related Analogs”,In: Nucleoside Analogues—Chemistry, Biology, and Medical Applications, Editor: Walker, R.T., et al., (eds.), Plenum Press, New York, 193-223, (1979).
Weng, J.H., et al., “Structure-activity relationships and receptor binding characteristics of 3-methylfentanyl derivatives”,Yaoxue Xuebao, 23(3), Abstract, 3 pages, (1990).
Catlow, et al., “Chemical Abstracts”, vol. 127:205575, 1997.
Hrib, et al., “Chemical Abstracts”,vol. 121:157558, 1994.
Hrib, et al., “Chemical Abstracts”, vol. 118:80954, 1993.
Janssen, Pharmaceutica, “Chemical Abstracts”, vol. 111:134153, 1989.
Janssens, et al., “Chemical Abstracts”, vol. 120:54556, 1994.
Suzuki, et al., “Chemical Abstracts”, vol. 126:104080, 1997.
Takasugi, et al., “Chemical Abstracts”, vol. 120:30773, 1994.
Uno, et al., “Chemical Abstracts”, vol. 106:176422, 1987.
Gong Leyi
Kertesz Denis John
Smith David Bernard
Talamas Francisco Xavier
Wilhelm Robert Stephen
Hall Robert C.
Raymond Richard L.
Syntex (U.S.A.) LLC
LandOfFree
Cyclic amine derivatives-CCR-3 receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyclic amine derivatives-CCR-3 receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclic amine derivatives-CCR-3 receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3601942